Noscendo GmbH’s Post

🌟 Next in a Project Series: ERDERA 🌟 Based on a strategic partnership, 𝐭𝐡𝐞 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐀𝐥𝐥𝐢𝐚𝐧𝐜𝐞 (𝐄𝐑𝐃𝐄𝐑𝐀) aims to improve the health and well-being of the 30 million people living with rare diseases in Europe. We are honored to be a part of the transformative journey of the ERDERA project, a groundbreaking initiative co-funded by the 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐔𝐧𝐢𝐨𝐧 and coordinated by National Institute of Health and Medical Research (𝐈𝐍𝐒𝐄𝐑𝐌), 𝐅𝐫𝐚𝐧𝐜𝐞. Fraunhofer IMM, Fraunhofer ITEM, and Fraunhofer IZI-BB institutes play a pivotal role in this ambitious endeavor. With our expertise in applied research, we are at the forefront of developing and optimizing advanced mRNA technologies. 🎯 Our Goals at Fraunhofer IMM: • Advance innovative mRNA nanoparticles, including lipid nanoparticles (LNP), extracellular vesicles (EVs), and biohybrids. • Demonstrate the scalability of targeted and optimized mRNA formulations. Together, we are paving the way for significant advancements in rare disease therapy, committing to the UN 2030 Agenda for Sustainable Development. For more updates, please visit https://lnkd.in/eZZ3-w-V #ERDERA #RareDiseaseResearch #mRNAInnovation #Fraunhofer #HealthInnovation #EUfunded #SDG

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Bill Morice, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss testing innovations for Alzheimer’s disease and cognitive impairments, and how laboratorians can responsibly help shape the future of healthcare. https://bit.ly/3WeqAck

How is Providence transforming healthcare through research? By pursuing the promise of genomic medicine for all, helping bring new medical devices and technologies to market, advancing personalized treatments for cancer and other diseases, reshaping standards of care and so much more. Learn about our research and its impact in the new 2023 Providence Research Network Annual Report.      #thefutureofhealth #research #healthcaretransformation #clinicaltrials      https://lnkd.in/ghDjDMiW 

The #EU Health Technology Assessment (#HTA) Regulation will apply from 12 January 2025 to #oncology products and #ATMPs, including #OrphanMedicinalProducts (OMPs) with these indications. From 13 January 2028, the new procedure will apply to all OMPs, irrespective of the therapeutic indication. 💻Join us for the fifth episode in our #LifeScienceLectures webinar series, where we’ll discuss challenges in evidence generation for #OMPs and experiences with national HTA procedures, to explore possible methodological approaches that will ensure joint clinical assessments (#JCAs) speed up #access to treatments for people living with #RareDiseases. 🔗 Register here: https://lnkd.in/dp_XMUgV Our panel: 🗣️ Maurizio Scarpa, Coordinator, ERN for Rare Hereditary Metabolic Diseases (MetabERN) 🗣️ Silke Honsek, Senior Manager, International Market Access & New Assets, AOP Health 🗣️ Mark Sheehan, Associate Professor, NIHR Oxford Biomedical Research Centre 🗣️ Sheela Upadhyaya, Life Sciences Consultant Specialist 🎤Moderated by EUCOPE's Alexander Natz 📅 3 June 2024 (16:00 - 17:00 CET) 📺 The new EU HTA procedure: How can JCAs support access to OMPs for people living with rare diseases

We need to see the data rather than just an on-stage chat, but if this stands up it’s a pretty cool result. And a 1000-mouse trial is exactly what we need to see more of in longevity science—this is what a few billion in funding (which isn’t much in the wider economy) can do! Also some good context on how this fits in with the scale of previous results in Yuri’s post:

How can clinical practice guidelines impact adoption of genomic testing into routine medical care? Join us for a public hybrid workshop on October 29 to discuss improving patient care by examining how guidelines effect patients, clinicians, laboratory partners, payers, and test developers. Register here: https://ow.ly/JgzX50Twstm #GenomicsRT #NatlCancerForum #Genomics #GeneticTesting

Billy Boyle, CEO & Co-founder of Owlstone Medical, recently participated in an interview with Sonia Nicholas at SelectScience®, where he discussed the founding of Owlstone Medical and its mission to improve patient outcomes through early disease detection. Early detection of cancer significantly increases survival rates and reduces healthcare costs. At Owlstone Medical, we utilize our Breath Biopsy technology to analyze volatile organic compounds (VOCs) in exhaled breath, which can serve as biomarkers for disease diagnosis. To deepen our understanding of human breath composition—both in healthy individuals and those with various diseases—we have developed the Breath Biopsy VOC Atlas®. Watch the full interview to hear Billy discuss our motivations, the challenges within the industry, and how we are advancing research in breath diagnostics. ➡️https://ow.ly/tGyE50UbY5Q

🚀 Homi-Lung: A 5-year journey to better cardiovascular and respiratory care We’re excited to introduce the Homi-Lung project, an ambitious 5-year initiative funded under the EU’s Horizon Europe programme (grant agreement No 101137148). This project aims to bridge the gap between research and clinical practice, focusing on the crucial links between pneumonia and cardiovascular diseases. With a world-class consortium led by CHU de Nantes, and partners across Europe and the USA, the project will explore innovative clinical trials, pre-clinical studies, genomic, transcriptomic and artificial intelligence technologies to improve diagnostics, treatment protocols, and patient care. Homi-Lung operates across various disciplines, including infectious diseases, cardiovascular research, and AI, with the goal of reducing the burden of CVRDs and pneumonia on healthcare systems. The collaboration between hospitals, biotech companies, and universities will ensure a multifaceted approach to understanding and combating the long-term impact of pneumonia on cardiovascular health. Keep following us as we bring life-changing innovations into real-world healthcare! 📅 Follow our progress on the website linked in the comments! #HorizonEurope #HomiLung #MedicalResearch #PneumoniaCare #CardiovascularHealth

How can clinical practice guidelines impact adoption of genomic testing into routine medical care? Join us for a public hybrid workshop on October 29 to discuss improving patient care by examining how guidelines effect patients, clinicians, laboratory partners, payers, and test developers. Register here: https://ow.ly/TFLo50Tws8A #GenomicsRT #NatlCancerForum #Genomics #GeneticTesting

How can clinical practice guidelines impact adoption of genomic testing into routine medical care? Join us for a public hybrid workshop on October 29 to discuss improving patient care by examining how guidelines effect patients, clinicians, laboratory partners, payers, and test developers. Register here: https://ow.ly/wmTw50Twsum #GenomicsRT #NatlCancerForum #Genomics #GeneticTesting